STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain ...

Background. A 20-year-old woman presented to a specialist epilepsy center with a 3-year history of drug-resistant epileptic seizures, progressive myoclonus, ataxia, and cognitive decline.

Based on reported cases, Unverricht-Lundborg disease, also known as progressive myoclonic epilepsy-1A, EPM1, is more common in Finland than anywhere else in the world, a new study finds. The ...

A new study shows that wearable sensor technology can be used to reliably assess the occurrence of myoclonic jerks in patients with epilepsy also in the home environment. A new study by the University ...

Fast, reliable and automatic assessment of the severity of myoclonic jerks from video footage is now possible, thanks to an algorithm using deep convolutional neural network architecture and ...

Researchers from Autifony Therapeutics Ltd. presented preclinical data for the novel potent Kv3 channel positive modulator, AUT-00201, which is currently being evaluated in early clinical studies for ...

Fast, reliable and automatic assessment of the severity of myoclonic jerks from video footage is now possible, thanks to an algorithm using deep convolutional neural network architecture and ...

Based on reported cases, Unverricht-Lundborg disease, also known as progressive myoclonic epilepsy-1A, EPM1, is more common in Finland than anywhere else in the world, a new study finds. Based on ...